Noteworthy events during the week of March 22 – 28 for healthcare investors (some could be canceled/postponed due to COVID-19).
SUNDAY (3/22): European Society for Blood and Marrow Transplantation Annual Meeting, Madrid (4 days).
WEDNESDAY (3/25): FDA action date for Celgene‘s (NYSE:BMY) ozanimod for relapsing multiple sclerosis and Zogenix‘s (NASDAQ:ZGNX) Fintepla for Dravet syndrome.
THURSDAY (3/26): FDA action date for Heron Therapeutics‘ (NASDAQ:HRTX) HTX-011 for postoperative pain and IntelGenx‘s (OTCQX:IGXT) Rizaport for acute migraine.
SATURDAY (3/28): American College of Cardiology Annual Scientific Session & Expo, Chicago (3 days). Amarin (NASDAQ:AMRN): Eight presentations on Vascepa and its effects on CV risk. MyoKardia (NASDAQ:MYOK): Phase 2 data on mavacamten in symptomatic non-obstructive hypertrophic cardiomyopathy. Johnson & Johnson (NYSE:JNJ): Four abstracts on Xarelto including Phase 3 data in symptomatic peripheral artery disease.
FDA action date for Rockwell Medical‘s (NASDAQ:RMTI) IV Triferic (decision may be announced the day before).
Update: The FDA action date for
Zogenix’s Fintepla was extended to June 25 due to an amendment to the
filing (additional data submitted per agency request).
https://seekingalpha.com/news/3553839-key-events-next-week-healthcare
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.